X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2172) 2172
Book Review (319) 319
Publication (262) 262
Newsletter (137) 137
Book Chapter (20) 20
Conference Proceeding (13) 13
Newspaper Article (10) 10
Magazine Article (5) 5
Dissertation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
vemurafenib (2243) 2243
melanoma (1373) 1373
index medicus (1343) 1343
humans (1225) 1225
oncology (943) 943
braf (673) 673
mutation (652) 652
cancer (617) 617
melanoma - drug therapy (613) 613
proto-oncogene proteins b-raf - genetics (571) 571
metastatic melanoma (539) 539
male (517) 517
female (509) 509
proto-oncogene proteins b-raf - antagonists & inhibitors (444) 444
dabrafenib (435) 435
survival (408) 408
middle aged (407) 407
melanoma - pathology (382) 382
melanoma - genetics (378) 378
care and treatment (340) 340
metastasis (335) 335
aged (321) 321
ipilimumab (321) 321
skin neoplasms - drug therapy (307) 307
dermatology (306) 306
adult (301) 301
open-label (296) 296
antineoplastic agents - therapeutic use (292) 292
research (288) 288
mutations (275) 275
immunotherapy (262) 262
animals (241) 241
resistance (241) 241
skin neoplasms - pathology (240) 240
drug therapy (228) 228
sulfonamides - therapeutic use (226) 226
therapy (225) 225
cell line, tumor (224) 224
genetic aspects (223) 223
indoles - therapeutic use (223) 223
tumors (218) 218
improved survival (215) 215
gene mutations (210) 210
treatment outcome (208) 208
analysis (203) 203
protein kinase inhibitors - therapeutic use (188) 188
mek inhibition (187) 187
inhibition (181) 181
kinases (179) 179
sulfonamides - pharmacology (173) 173
article (172) 172
indoles - pharmacology (171) 171
neoplasms (170) 170
trametinib (170) 170
chemotherapy (168) 168
health aspects (168) 168
skin neoplasms - genetics (168) 168
antineoplastic agents - pharmacology (166) 166
proto-oncogene proteins b-raf - metabolism (166) 166
pharmacology & pharmacy (164) 164
acquired-resistance (159) 159
aged, 80 and over (158) 158
cell biology (155) 155
multicenter (153) 153
braf inhibitor (151) 151
sulfonamides - adverse effects (151) 151
antineoplastic agents - adverse effects (147) 147
medicine, research & experimental (147) 147
indoles - adverse effects (145) 145
targeted therapy (145) 145
protein kinase inhibitors - pharmacology (144) 144
melanoma - metabolism (141) 141
mice (139) 139
malignant-melanoma (135) 135
drug resistance (130) 130
melanoma - secondary (129) 129
patients (129) 129
apoptosis (123) 123
molecular targeted therapy (122) 122
prognosis (120) 120
retrospective studies (120) 120
antineoplastic combined chemotherapy protocols - therapeutic use (117) 117
dosage and administration (117) 117
neoplasm metastasis (117) 117
metastases (116) 116
pathology (116) 116
skin cancer (115) 115
braf mutation (114) 114
activation (112) 112
expression (112) 112
inhibitors (111) 111
clinical trials (110) 110
sulfonamides - administration & dosage (110) 110
b-raf (109) 109
development and progression (107) 107
pathway (106) 106
indoles - administration & dosage (104) 104
braf inhibitors (102) 102
medicine & public health (102) 102
young adult (102) 102
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2233) 2233
French (50) 50
German (31) 31
Spanish (9) 9
Polish (6) 6
Czech (5) 5
Russian (5) 5
Korean (4) 4
Dutch (3) 3
Chinese (2) 2
Hungarian (1) 1
Japanese (1) 1
Slovak (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


La Revue de medecine interne, ISSN 0248-8663, 06/2019, Volume 40, p. A177
La maladie d'Erdheim Chester est une histiocytose non-largerhansienne rare du groupe L. Elle peut toucher tous les organes et en particulier les os et... 
Vemurafenib
Journal Article
American Journal of Clinical Dermatology, ISSN 1175-0561, 02/2013, Volume 14, Issue 1, p. 65
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2019, Volume 30, Issue 1, pp. 155 - 156
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 07/2018, Volume 155, p. 725
A series of novel selective BRAF.sup.V600E inhibitory agents (Compound 1--16)... 
Vemurafenib | Dioxane | Analysis | Pharmaceutical biotechnology
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 07/2016, Volume 34, Issue 20, pp. 2432 - U200
Journal Article
European Journal of Cancer, ISSN 0959-8049, 04/2019, Volume 111, pp. 8 - 11
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 07/2017, Volume 18, Issue 7, pp. 863 - 873
Background Dabrafenib plus trametinib improves clinical outcomes in BRAF(V600)-mutant metastatic melanoma without brain metastases; however, the activity of... 
SURVIVAL | THERAPY | PEMBROLIZUMAB | MEK INHIBITION | ONCOLOGY | MUTANT MELANOMA | PATHWAY | CUTANEOUS MELANOMA | DOUBLE-BLIND | IPILIMUMAB | VEMURAFENIB
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2018, Volume 75, Issue 3, pp. 329 - 334
Journal Article
Der Ophthalmologe, ISSN 0941-293X, 08/2019, Volume 116, Issue 8, p. 785
Unter Kombinationstherapie mit Cobimetiniba/Vemurafenib zur Behandlung des BRAF-V600-positiven metastasierten Melanoms kann es zu einer symptomatischen oder... 
Vemurafenib | Gene mutations | Melanoma | Metastasis
Journal Article
Annals of Pharmacotherapy, ISSN 1060-0280, 11/2011, Volume 45, Issue 11, pp. 1399 - 1405
Journal Article
by Su, HH and Wu, W and Guo, Y and Chen, HD and Shan, SJ
BRITISH JOURNAL OF DERMATOLOGY, ISSN 0007-0963, 01/2018, Volume 178, Issue 1, pp. 261 - 264
Erdheim-Chester disease (ECD), a type of systemic non-Langerhans cell histiocytosis, is uncommon and characterized by the accumulation of CD68(+)CD1a(-) foamy... 
LANGERHANS CELL HISTIOCYTOSIS | INVOLVEMENT | VEMURAFENIB | DERMATOLOGY
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2014, Volume 32, Issue 33, pp. 3697 - 3697
Purpose Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in... 
METASTATIC MELANOMA | RAF INHIBITION | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | IMPROVED SURVIVAL | MECHANISMS | MUTATIONS | OVERCOME | VEMURAFENIB
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 10, pp. 2581 - 2587
The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive... 
Dacarbazine | Vemurafenib | Melanoma | BRAF mutation | Index Medicus | vemurafenib | melanoma | Original | Editor's Choice | dacarbazine
Journal Article
Nature, ISSN 0028-0836, 06/2018, Volume 558, Issue 7711, pp. 605 - 609
Reprogramming of mRNA translation has a key role in cancer development and drug resistance(1). However, the molecular mechanisms that are involved in this... 
CELLS | MELANOMA | INHIBITION | TRANSFER-RNAS | MULTIDISCIPLINARY SCIENCES | KINASE | IMPROVED SURVIVAL | MUTATIONS | HUMAN CANCER | VEMURAFENIB | RIBOSOME | Phosphorylation | Humans | Melanoma, Experimental - drug therapy | Male | Uridine - genetics | RNA, Messenger - metabolism | Vemurafenib - therapeutic use | Melanoma - genetics | RNA, Transfer - genetics | Carrier Proteins - chemistry | Female | Codon - genetics | Codon - drug effects | RNA, Transfer - chemistry | Uridine - chemistry | Signal Transduction | RNA, Transfer - metabolism | RNA, Messenger - genetics | Melanoma, Experimental - pathology | Melanoma - pathology | Mice, SCID | Vemurafenib - pharmacology | Zebrafish - genetics | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Mechanistic Target of Rapamycin Complex 2 - metabolism | Drug Resistance, Neoplasm - genetics | Animals | Carrier Proteins - metabolism | Melanoma, Experimental - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Mice, Inbred NOD | Protein Biosynthesis - drug effects | Uridine - metabolism | Mice | Drug Resistance, Neoplasm - drug effects | Care and treatment | Codon | Oncology, Experimental | Melanoma | Research | Genetic translation | Cancer | Enzymes | Physiological aspects | Development and progression | Protein biosynthesis | Transfer RNA | Short term | Therapy | Transformation | Genomes | mRNA | Kinases | Proteins | Signal transduction | Translation | Cell survival | tRNA | MAP kinase | Pharmacology | Decoding | Metabolism | Gene expression | Chemical compounds | Survival | Molecular chains | 1-Phosphatidylinositol 3-kinase | Signaling | Molecular modelling | Protein synthesis | Uridine | Glycolysis | Mutation | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 7, pp. 667 - 673
Purpose To report 5-year landmark analysis efficacy and safety outcomes in patients with BRAF V600-mutant metastatic melanoma (MM) who received BRAF inhibitor... 
MULTICENTER | MONOTHERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | POOLED ANALYSIS | IMPROVED SURVIVAL | OPEN-LABEL | PHASE-3 | NIVOLUMAB | VEMURAFENIB
Journal Article
LANCET ONCOLOGY, ISSN 1470-2045, 09/2016, Volume 17, Issue 9, pp. 1178 - 1179
Journal Article
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, ISSN 1610-0379, 09/2018, Volume 16, pp. 40 - 40
Conference Proceeding
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 50, Issue 3, pp. 611 - 621
Abstract Background & Aim Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis. We investigated the BRAF kinase... 
Hematology, Oncology and Palliative Medicine | Vemurafenib | Symptomatic brain metastases | Tumour regression | BRAF inhibitor | Safety | Advanced melanoma | BRAF mutation
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.